Dermatology’s growing focus on skin longevity demands clear definitions, validated outcomes, and rigorous evidence beyond anti-aging claims.
|Articles|August 1, 2004
FDA panel rejects Allergan's Tazoral
National report - The benefits of Allergan's proposed oral psoriasis drug, Tazoral, do not outweigh possible risks of birth defects and bone loss, a U.S. Food and Drug Administration advisory panel has decided.
Advertisement
Advertisement
Related to this article
Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Advertisement
Advertisement
Trending on Dermatology Times
1
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
Nonsteroidal Topicals Guide Special-Site Psoriasis Treatment Decisions
4
Fall Clinical 2026: The Data and Expert Advice Shaping Dermatology Practice
5